Ibiayi Dagogo-Jack1, Philicia Moonsamy2, Justin F Gainor1, Jochen K Lennerz3, Zofia Piotrowska1, Jessica J Lin1, Inga T Lennes1, Lecia V Sequist1, Alice T Shaw4, Kelly Goodwin5, Sara E Stevens5, Andrew Do5, Subba R Digumarthy6, Kristin Price7, Alona Muzikansky8, Aaron N Hata1, Rebecca S Heist9. 1. Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 2. Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts. 3. Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts. 4. Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Novartis Institutes of Biomedical Research, Cambridge, Massachusetts. 5. Massachusetts General Hospital Cancer Center, Boston, Massachusetts. 6. Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. 7. Guardant Health, Redwood City, California. 8. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 9. Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: rheist@partners.org.
Abstract
INTRODUCTION: Capmatinib is approved for MET exon 14-altered NSCLC on the basis of activity in targeted therapy-naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor. METHODS: Patients with advanced NSCLC harboring MET amplification or MET exon 14 skipping alterations received capmatinib 400 mg twice daily. The primary end point was the objective response rate. Secondary end points included progression-free survival, disease control rate (DCR), intracranial response rate, and overall survival. Circulating tumor DNA was analyzed to identify capmatinib resistance mechanisms. RESULTS: A total of 20 patients were enrolled between May 2016 and November 2019, including 15 patients with MET skipping alterations and five patients with MET amplification. All patients had received crizotinib; three had also received other MET-directed therapies. The median interval between crizotinib and capmatinib was 22 days (range: 4-374). Two patients (10%) achieved an objective response to capmatinib and 14 had stable disease, yielding a DCR of 80%. Among five patients who discontinued crizotinib for intolerance, the DCR was 83%, including two patients with the best tumor shrinkage of -25% and -28%. Intracranial DCR among four patients with measurable brain metastases was 100%, with no observed intracranial objective responses. Overall, the median progression-free survival and overall survival were 5.5 (95% confidence interval: 1.3-11.0) and 11.3 (95% confidence interval: 5.5-not reached) months, respectively. MET D1228 and Y1230 mutations and MAPK alterations were recurrently detected in postcrizotinib, precapmatinib plasma. New and persistent MET mutations and MAPK pathway alterations were detected in plasma at progression on capmatinib. CONCLUSIONS: Capmatinib has modest activity in crizotinib-pretreated MET-altered NSCLC, potentially owing to overlapping resistance mechanisms.
INTRODUCTION: Capmatinib is approved for MET exon 14-altered NSCLC on the basis of activity in targeted therapy-naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor. METHODS: Patients with advanced NSCLC harboring MET amplification or MET exon 14 skipping alterations received capmatinib 400 mg twice daily. The primary end point was the objective response rate. Secondary end points included progression-free survival, disease control rate (DCR), intracranial response rate, and overall survival. Circulating tumor DNA was analyzed to identify capmatinib resistance mechanisms. RESULTS: A total of 20 patients were enrolled between May 2016 and November 2019, including 15 patients with MET skipping alterations and five patients with MET amplification. All patients had received crizotinib; three had also received other MET-directed therapies. The median interval between crizotinib and capmatinib was 22 days (range: 4-374). Two patients (10%) achieved an objective response to capmatinib and 14 had stable disease, yielding a DCR of 80%. Among five patients who discontinued crizotinib for intolerance, the DCR was 83%, including two patients with the best tumor shrinkage of -25% and -28%. Intracranial DCR among four patients with measurable brain metastases was 100%, with no observed intracranial objective responses. Overall, the median progression-free survival and overall survival were 5.5 (95% confidence interval: 1.3-11.0) and 11.3 (95% confidence interval: 5.5-not reached) months, respectively. MET D1228 and Y1230 mutations and MAPK alterations were recurrently detected in postcrizotinib, precapmatinib plasma. New and persistent MET mutations and MAPK pathway alterations were detected in plasma at progression on capmatinib. CONCLUSIONS: Capmatinib has modest activity in crizotinib-pretreated MET-altered NSCLC, potentially owing to overlapping resistance mechanisms.
Authors: Nancy U Lin; Eudocia Q Lee; Hidefumi Aoyama; Igor J Barani; Daniel P Barboriak; Brigitta G Baumert; Martin Bendszus; Paul D Brown; D Ross Camidge; Susan M Chang; Janet Dancey; Elisabeth G E de Vries; Laurie E Gaspar; Gordon J Harris; F Stephen Hodi; Steven N Kalkanis; Mark E Linskey; David R Macdonald; Kim Margolin; Minesh P Mehta; David Schiff; Riccardo Soffietti; John H Suh; Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen Journal: Lancet Oncol Date: 2015-05-27 Impact factor: 41.316
Authors: Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: Paul K Paik; Enriqueta Felip; Remi Veillon; Hiroshi Sakai; Alexis B Cortot; Marina C Garassino; Julien Mazieres; Santiago Viteri; Helene Senellart; Jan Van Meerbeeck; Jo Raskin; Niels Reinmuth; Pierfranco Conte; Dariusz Kowalski; Byoung Chul Cho; Jyoti D Patel; Leora Horn; Frank Griesinger; Ji-Youn Han; Young-Chul Kim; Gee-Chen Chang; Chen-Liang Tsai; James C-H Yang; Yuh-Min Chen; Egbert F Smit; Anthonie J van der Wekken; Terufumi Kato; Dilafruz Juraeva; Christopher Stroh; Rolf Bruns; Josef Straub; Andreas Johne; Jürgen Scheele; John V Heymach; Xiuning Le Journal: N Engl J Med Date: 2020-05-29 Impact factor: 91.245
Authors: Rebecca S Heist; Lecia V Sequist; Darrell Borger; Justin F Gainor; Ronald S Arellano; Long P Le; Dora Dias-Santagata; Jeffrey W Clark; Jeffrey A Engelman; Alice T Shaw; A John Iafrate Journal: J Thorac Oncol Date: 2016-06-22 Impact factor: 15.609
Authors: Justin I Odegaard; John J Vincent; Stefanie Mortimer; James V Vowles; Bryan C Ulrich; Kimberly C Banks; Stephen R Fairclough; Oliver A Zill; Marcin Sikora; Reza Mokhtari; Diana Abdueva; Rebecca J Nagy; Christine E Lee; Lesli A Kiedrowski; Cloud P Paweletz; Helmy Eltoukhy; Richard B Lanman; Darya I Chudova; AmirAli Talasaz Journal: Clin Cancer Res Date: 2018-04-24 Impact factor: 12.531
Authors: Lars D Engstrom; Ruth Aranda; Matthew Lee; Elizabeth A Tovar; Curt J Essenburg; Zachary Madaj; Harrah Chiang; David Briere; Jill Hallin; Pedro P Lopez-Casas; Natalia Baños; Camino Menendez; Manuel Hidalgo; Vanessa Tassell; Richard Chao; Darya I Chudova; Richard B Lanman; Peter Olson; Lyudmilla Bazhenova; Sandip Pravin Patel; Carrie Graveel; Mizuki Nishino; Geoffrey I Shapiro; Nir Peled; Mark M Awad; Pasi A Jänne; James G Christensen Journal: Clin Cancer Res Date: 2017-08-01 Impact factor: 12.531
Authors: Alexander Drilon; Jeffrey W Clark; Jared Weiss; Sai-Hong Ignatius Ou; D Ross Camidge; Benjamin J Solomon; Gregory A Otterson; Liza C Villaruz; Gregory J Riely; Rebecca S Heist; Mark M Awad; Geoffrey I Shapiro; Miyako Satouchi; Toyoaki Hida; Hidetoshi Hayashi; Danielle A Murphy; Sherry C Wang; Sherry Li; Tiziana Usari; Keith D Wilner; Paul K Paik Journal: Nat Med Date: 2020-01-13 Impact factor: 53.440
Authors: Trever G Bivona; Collin M Blakely; Julia K Rotow; Philippe Gui; Wei Wu; Victoria M Raymond; Richard B Lanman; Frederic J Kaye; Nir Peled; Ferran Fece de la Cruz; Brandon Nadres; Ryan B Corcoran; Iwei Yeh; Boris C Bastian; Petr Starostik; Kimberly Newsom; Victor R Olivas; Alexander M Wolff; James S Fraser; Eric A Collisson; Caroline E McCoach; D Ross Camidge; Jose Pacheco; Lyudmila Bazhenova; Tianhong Li Journal: Clin Cancer Res Date: 2019-09-23 Impact factor: 12.531
Authors: Parneet K Cheema; Shantanu O Banerji; Normand Blais; Quincy S-C Chu; Patrice Desmeules; Rosalyn A Juergens; Natasha B Leighl; Brandon S Sheffield; Paul F Wheatley-Price; Barbara L Melosky Journal: Curr Oncol Date: 2021-11-09 Impact factor: 3.677